- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.10. | Enzymatica AB Q3 Loss Decreases | 1 | RTTNews | ||
| 29.10. | Enzymatica AB: Quarterly report Q3/2026 - ColdZyme enters new markets | 183 | GlobeNewswire (Europe) | Third quarter· Net sales reached SEK 14.6 (15.0) million.· The operating result totaled SEK -3.9 (-8.2) million.· Earnings per share, basic and diluted, were SEK -0.02 (-0.03).· Cash flow from operating... ► Artikel lesen | |
| 28.10. | Enzymatica AB: Truls Möregårdh invests in Enzymatica and becomes ColdZyme ambassador | 215 | GlobeNewswire (Europe) | International table tennis star Truls Möregårdh, a double Olympic silver medallist at Paris 2024, World Championship silver medallist and winner of multiple international titles, is investing in Swedish... ► Artikel lesen | |
| 27.10. | Enzymatica AB: Guðmundur Pálmason steps down from Enzymatica's Board of Directors | 156 | GlobeNewswire (Europe) | Enzymatica AB (publ) announces that Guðmundur Pálmason has decided to step down from the company's Board of Directors for personal reasons, effective 28 October 2026.Guðmundur Pálmason has served on... ► Artikel lesen | |
| 22.10. | Enzymatica AB: Bulletin from the Extraordinary General Meeting of Enzymatica AB (publ) on 22 October 2026 | 174 | GlobeNewswire (Europe) | On 22 October 2026, the shareholders of Enzymatica AB (publ) (the "Company") held an Extraordinary General Meeting. The following principal resolutions were adopted at the Meeting.
Resolution on the... ► Artikel lesen | |
| ENZYMATICA Aktie jetzt für 0€ handeln | |||||
| 21.10. | Enzymatica AB: Enzymatica enters MENA - signs distribution agreement for ColdZyme in Jordan and Iraq | 160 | GlobeNewswire (Europe) | Lund, Sweden, [DATE] 2026. Enzymatica AB (publ) has signed a long-term exclusive distribution agreement with MedonyX, an MMDS-backed company, for the registration, marketing, sale and distribution of... ► Artikel lesen | |
| 16.10. | Enzymatica AB: STADA launches Virustad in Germany - based on Enzymatica's ColdZyme technology | 749 | GlobeNewswire (Europe) | STADA has launched the oral spray Virustad in the German pharmacy market. Virustad is built on Enzymatica's clinically documented ColdZyme® technology. The launch follows the partnership agreement signed... ► Artikel lesen | |
| 27.08. | Enzymatica AB: Enzymatica strengthens its management team with commercial and scientific expertise | 455 | GlobeNewswire (Europe) | Enzymatica Enzymatica is strengthening its management team with the addition of Nordic Marketing and Sales Director Joakim Tingström Nordin and Chief Scientist and Head of Production Iceland Bjarki... ► Artikel lesen | |
| 16.07. | Enzymatica AB: Quarterly report Q2/2026 Continued focus on international expansion and a stronger organization | 328 | GlobeNewswire (Europe) | Second quarter· Net sales reached SEK 7,1 (8.3) million.· The operating result totaled SEK -12.6 (-14.9) million.· Earnings per share, basic and diluted, were SEK -0.05 (-0.06).· Cash flow from operating... ► Artikel lesen | |
| 24.06. | Enzymatica AB: The evidence base for ColdZyme remains unchanged - PLOS ONE notice concerns the presentation of the Berlin II article, not the evidence base for ColdZyme | 252 | GlobeNewswire (Europe) | Enzymatica AB (publ) notes that the scientific journal PLOS ONE has published an Expression of Concern regarding an article on the company's placebo-controlled Berlin II study from 2023. The notice... ► Artikel lesen | |
| 09.06. | Enzymatica AB: Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme's continued growth in the Nordics | 725 | GlobeNewswire (Europe) | Enzymatica has appointed Joakim Tingström Nordin as its new Nordic Marketing and Sales Director. He will assume the role in August and will be responsible for driving ColdZyme's commercial development... ► Artikel lesen | |
| 07.05. | Enzymatica AB: Bulletin from annual general meeting of Enzymatica AB (publ) on 7 May 2026 | 365 | GlobeNewswire (Europe) | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Enzymatica AB (publ) held its annual... ► Artikel lesen | |
| 28.04. | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | 1.491 | GlobeNewswire (Europe) | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| 31.03. | Enzymatica AB: Enzymatica and STADA sign partnership agreement for Germany and Austria | 1.046 | GlobeNewswire (Europe) | Regulatory press release
• The new partnership agreement covers the launch and distribution of Enzymatica's ColdZyme® technology in oral spray form in Germany and Austria
• The partnership combines... ► Artikel lesen | |
| 18.02. | Enzymatica AB: Year-end report 2025: New CEO takes the helm - initiates the next phase of Enzymatica's international expansion | 662 | PR Newswire | LUND, Sweden, Feb. 18, 2026 /PRNewswire/ --
Fourth quarterJanuary-December
Net sales reached SEK 18.3 (17.2) millionThe operating result totaled SEK -10.2 (-13.7) million.Earnings... ► Artikel lesen | |
| 11.12.25 | Enzymatica AB: Enzymatica appoints Acting CFO during transition period | 293 | GlobeNewswire (Europe) | Enzymatica today announces the appointment of Kristina Rylander as Acting CFO during a transition period in the spring of 2026. She will assume the role on 1 March 2026, following the departure of the... ► Artikel lesen | |
| 20.11.25 | Enzymatica AB: Enzymatica enters partnership with the UK Sports Institute to support athlete health and performance | 477 | GlobeNewswire (Europe) | ColdZyme, the mouth spray developed by Enzymatica AB, has entered into a new partnership with the UK Sports Institute (UKSI) to support the institute's work in promoting athlete health and wellbeing.
The... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 56,52 | -0,98 % | Bayer-Aktie mit +194% - droht jetzt ein Rückschlag? | Die Bayer-Aktie notiert nach einem Wochengewinn von mehr als +7% bei 54,24 €. Damit erreicht der Kurs eine wichtige Widerstandszone und testet zugleich den langfristigen Abwärtstrend. Während der RSI... ► Artikel lesen | |
| NOVO NORDISK | 36,250 | -0,63 % | Novo-Nordisk-Aktie: 3 Patentabläufe - droht jetzt die nächste Gewinnfalle? | Die Novo-Nordisk-Aktie hat nach den überraschend starken Quartalszahlen um rund +5,6% auf 285,20 Dänische Kronen zugelegt. Doch eine neue Entwicklung könnte den Turnaround erheblich erschweren. In gleich... ► Artikel lesen | |
| PFIZER | 26,305 | +0,06 % | Dividendenbekanntmachungen (06.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AG BARR PLC GB00B6XZKY75 0,0382 GBP EUR ALLIANCE RESOURCE PARTNERS LP US01877R1086 0,6 USD 0,5348 EUR AUBAY SA FR0000063737 - 0... ► Artikel lesen | |
| GILEAD SCIENCES | 153,28 | +0,14 % | Gilead erwartet FDA-Entscheidung über neue Zelltherapie - Mesoblast will Behandlung auf Erwachsene ausweiten | ||
| SANOFI | 85,90 | -0,49 % | DEUTSCHE BANK RESEARCH stuft SANOFI auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Sanofi nach Zahlen auf "Buy" mit einem Kursziel von 95 Euro belassen. Das Update zum dritten Quartal sei beeindruckend gewesen... ► Artikel lesen | |
| GSK | 22,730 | -0,74 % | "Halt bei Krebs"-Hotline von GSK: Persönliche Unterstützung für Menschen mit Krebs und ihre Angehörigen | München (ots) - - Die spezialisierte Expertenhotline* ist eine Anlaufstelle für Menschen mit Krebs, insbesondere mit Multiplem Myelom, Myelofibrose, Eierstock- oder Gebärmutterkrebs, sowie für ihre... ► Artikel lesen | |
| ABBVIE | 262,20 | -0,42 % | Eli Lilly kauft AtaiBeckley für 2,8 Milliarden Dollar - wer behandelt künftig die Patienten? | ||
| ASTRAZENECA | 166,00 | -0,75 % | JEFFERIES stuft ASTRAZENECA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca auf "Buy" mit einem Kursziel von 17500 Pence belassen. Analyst Michael Leuchten beschäftigte sich in einer... ► Artikel lesen | |
| INNOCAN PHARMA | 1,045 | -1,42 % | Innocan Pharma: Erste Tranche zu - was jetzt wichtig wird | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -2- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameCA83013Q8719 CORE... ► Artikel lesen | |
| VIATRIS | 18,422 | -1,39 % | Viatris Inc. Q3 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Viatris Inc. (VTRS):Earnings: -$325.3 million in Q3 vs. -$128.2 million in the same period last year.
EPS: -$0.28 in Q3 vs. -$0.11... ► Artikel lesen | |
| SINOPHARM | 1,904 | -2,01 % | SINOPHARM (01099): ANNOUNCEMENT (1) CONTINUING CONNECTED TRANSACTIONS: 2026 PROCUREMENT FRAMEWORK AGREEMENT, 2026 SALES FRAMEWORK AGREEMENT, 2026 EPC ... | ||
| HALEON | 4,017 | -0,30 % | 3 Verdoppler gefällig: 250 % Kurspotenzial bei Wasserstoff: Goldman Sachs Favoriten für Europa | © Foto: KI-generiert mit DALL-EGoldman Sachs stellt seine europäischen Aktienfavoriten für November neu auf. Die Deutsche Bank ersetzt HSBC, auch Carlsberg steigt auf. Bei drei Aktien sehen die Analysten... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 284,00 | +0,71 % | Ligand Pharmaceuticals: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million | JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc.... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 5,750 | 0,00 % | ACHIEVE LIFE SCIENCES, INC. - 10-Q, Quarterly Report |
ENZYMATICA AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENZYMATICA AB finden Sie auf Wallstreet Online.